{"page":"/blog/telehealth-advertising-rules","modified":"2026-11-10","license":"https://creativecommons.org/licenses/by/4.0/","columns":["Date","Actor","Target","What it concerns","Status","Source"],"rows":[["1 July 2025","California Attorney General","Healthline Media (health publisher)","Opt-out of targeted ads and purpose limits for article data","$1.55 million settlement","CA AG enforcement list"],["14 July 2025","FTC","Southern Health Solutions (NextMed)","GLP-1 program: hidden costs, fake reviews, unsupported weight-loss claims","$150,000 under a proposed order","Foley, 12 August 2025 (secondary)"],["9 September 2025","FDA","Hims & Hers and others","Warning letter on claims that compounded drugs match approved ones","Part of more than 100 letters posted 16 September 2025","Fortune, 16 September 2025 (secondary)"],["3 March 2026","FDA","Telehealth companies and online clinics","Thirty warning letters on compounded GLP-1 claims","Responses due within 15 working days","Frier Levitt, 9 March 2026 (secondary)"],["29 July 2026","FTC, Utah and California authorities","Hims & Hers Health","Pixels, server-side conversion tool and list uploads to Meta and Snap; \"private\" claims; subscription billing","Complaint pending in N.D. Cal.; no ruling seen","Alston & Bird, August 2026; Venable"]],"sourceUrls":[["https://oag.ca.gov/privacy/privacy-enforcement-actions"],["https://www.foley.com/insights/publications/2025/08/health-care-marketing-enforcement-ftc-targets-telehealth-company-for-deceptive-w/"],["https://fortune.com/2025/09/16/fda-weight-loss-drugmakers-false-misleading-advertising-telehealth"],["https://www.frierlevitt.com/articles/fda-warning-letters-hims-novo-nordisk-compounded-glp1/"],["https://www.alston.com/en/insights/publications/2026/08/ftc-lawsuit-hims-hers-rosca","https://www.venable.com/insights/publications/2026/08/ftc-and-states-take-action-against-hims-and-hers"]]}